Perrigo Hires Ex-FDA Director for New Role

Before you go, we thought you'd like these...
Before you go close icon

In hopes of expediting the regulatory applications and processes for newly developed drugs, Perrigo has created a position -- head of regulatory review -- and hired former Food and Drug Administration Director Keith Webber to fill the role, Perrigo announced yesterday.

Webber served in several positions with the FDA before joining Perrigo, including heading up the department that regulates prescription drugs, and as director of the FDA's generic-drug department, according to Perrigo's statement.

Commenting on Webber's appointment, Perrigo Chairman, President, and CEO Joseph Papa said, "He brings to us a wealth of strategic, scientific and regulatory experience from his years working with the FDA."


Speaking to Webber's role with Perrigo, Papa adde, "Keith will work closely with regulatory leadership to support new product selection and develop strategies and processes to achieve high quality applications and timely approvals, enabling us to bring quality, affordable products to the market."

Webber's appointment as head of regulatory review becomes effective Oct. 21, according to Perrigo.

The article Perrigo Hires Ex-FDA Director for New Role originally appeared on Fool.com.

Fool contributor Tim Brugger and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners